Ignite Creation Date:
2025-12-25 @ 1:21 AM
Ignite Modification Date:
2026-01-23 @ 5:42 PM
Study NCT ID:
NCT06682793
Status:
RECRUITING
Last Update Posted:
2025-09-09
First Post:
2024-11-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Sponsor:
A2 Biotherapeutics Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | RCC | View |
| None | Renal Cell Carcinoma | View |
| None | Kidney Cancer | View |
| None | Solid Tumor, Adult | View |
| None | Colorectal Cancer | View |
| None | Non-Small Cell Lung | View |
| None | NSCLC (Non-small Cell Lung Cancer) | View |
| None | Cancer | View |
| None | Colon Cancer | View |
| None | Rectal Cancer | View |
| None | Lung Cancer | View |
| None | CRC | View |
| None | Head and Neck Squamous Cell Cancer | View |
| None | HNSCC | View |
| None | Triple Negative Breast Cancer | View |
| None | TNBC | View |
| None | Colorectal Adenocarcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CAR T Cell | View |
| None | Solid Tumors | View |
| None | Allogeneic | View |
| None | T Cell | View |
| None | EGFR | View |
| None | HLA-A2 | View |
| None | Solid tumors expressing EGFR | View |
| None | CRC | View |
| None | Colorectal | View |
| None | Cell Therapy | View |
| None | Gene Therapy | View |
| None | Blocker | View |
| None | Cancer | View |
| None | NSCLC | View |
| None | Non small Cell Lung Cancer | View |
| None | Lung Cancer | View |
| None | renal cell carcinoma | View |
| None | RCC | View |
| None | Kidney Cancer | View |
| None | Renal cell cancer | View |
| None | Triple negative breast cancer | View |
| None | TNBC | View |